Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of midostaurin with daunorubicin/cytarabine in newly diagnosed FLT3-mutated AML
jRCT2080223859Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Midostaurin arm with Placebo arm (2 arms). Primary endpoint: Event-free survival. Started Apr 2018; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080223859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223859.